drugset / Trial / NCT00708656

The Colitis Once Daily Asacol Study

NCT00708656

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the safety and effectiveness of dosing mesalazine 800 mg tablets (Asacol®) at 2.4 g once daily versus divided doses three times daily in the maintenance of remission of ulcerative colitis.

Timeline

Start
2006-10
Primary completion
2010-07
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 800 mg Oral
Subject Mesalamine Small molecule 2.4 g Oral

Indications